Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix is a biotechnology company with an exciting pipeline of potential eye medication, including Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. The recent milestone of a streamlined path to approval for OTX-TKI, along with positive data for AXPAXLI in wet AMD, has bolstered confidence in the company's potential. However, like all biotech companies, there are inherent risks associated with investing, including stock price volatility and regulatory and commercial risks. Despite these risks, the strong potential for market success and innovative treatments make Ocular Therapeutix a promising investment opportunity.

Bears say

Ocular Therapeutix is valued at $5.55B and has a Buy rating with a $25 price target. The company's success heavily relies on its lead candidate Axpaxli, which is currently in Phase 3 clinical trials for wet AMD and NPDR. Risks include potential failure in clinical trials or inability to successfully commercialize, as well as potential intellectual property risks and stock price volatility. However, the recent successful Pre-NDA meeting with the FDA for Axpaxli and potential approval in 2027 suggest a promising outlook for the company's pipeline.

Ocular Therapeutix (OCUL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ocular Therapeutix (OCUL) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.